Immune responses to adenovirus and adeno-associated virus in humans

Gene Therapy

Volumn 6, Issue 9, 1999, Pages 1574-1583

  Chirmule, N ^a,c   Propert, K J ^a   Magosin, S A ^a   Qian, Y ^a   Qian, R ^a   Wilson, J M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AAV; Adenovirus; Cytokines; Humans; Lymphoproliferation; Neutralizing antibodies

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GENE THERAPY; HELPER CELL; HUMAN; HUMAN ADENOVIRUS; IMMUNITY; MALE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; T LYMPHOCYTE SUBPOPULATION; VIRUS NEUTRALIZATION;

ADENOVIRIDAE; ADULT; ANTIBODIES, VIRAL; B-LYMPHOCYTES; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELLS, CULTURED; CHI-SQUARE DISTRIBUTION; CYSTIC FIBROSIS; CYTOKINES; DEPENDOVIRUS; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; DNA VIRUSES; HUMAN ADENOVIRUS;

EID: 0032853699     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300994     Document Type: Article

References (30)

1. Wilson J. Gene therapy for cystic fibrosis: challenges and future directions. J Clin Invest 1995; 96: 2547-2554.
2. Wilson JM. Adenoviruses as gene-delivery vehicles. New Engl J Med 1996; 334: 1185-1187.
3. Crystal R. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270: 404-410.
4. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Therapy 1995; 2: 357-362.
5. Koeberl DD et al. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA 1997; 94: 1426-1431.
6. Bromberg JS, Debruyne LA, Qin L. Interactions between the immune system and gene therapy vectors: bidirectional regulation of response and expression. Adv Immunol 1998; 69: 353-409.
7. Schmitz H, Wigand R, Henrich W. Worldwide epidemiology of human adenovirus infections. Am J Epidemiol 1983; 117: 455-466.
8. Crystal RG et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42-51.
9. Knowles M et al. A double-blind vehicle controlled study of adenoviral vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. New Engl J Med 1995; 333: 823-831.
10. Rosenfeld MA et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-155.
11. Gahery-Segard H et al. Phase I trial of recombinant adenovirus gene transfer in lung cancer: longitudinal study of the immune responses to transgene and viral products. J Clin Invest 1997; 100: 2218-2226.
12. Wold SM, Tollefson AE, Hermiston TW. Strategies of immune modulation by adenoviruses. In: G McFadden (ed). Viroceptors, Virokines and Related Immune Modulators Encoded by DAN Viruses. RG Landes: 1994, pp 147-185.
13. Takafuji ET, Gaydos JC, Allen RG, Top FH. Simultaneous administration of live, enteric coated adenovirus 4, 7 and 21 vaccines: safety and immunogenecity. J Infect Dis 1979; 140: 48-53.
14. Atchinson R. Adenovirus-associated defective virus particles. Science 1965; 149: 754-756.
15. McKeon C, Ramulski RJ. NIDDK workshop on AAV vectors: gene transfer into quiescent cells. Hum Gene Ther 1996; 7: 1615-1619.
16. Kotin RM. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 1994; 5: 793-801.
17. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098-8108.
18. Fisher KJ et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med 1997; 3: 306-312.
19. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune responses to transgene products in muscle fibers. J Virol 1998; 72: 4212-4223.
20. Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated transfer to mouse liver. Gene Therapy 1996; 3: 412-420.
21. Guibinga G-H et al. Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles. J Virol 1998; 72: 4601-4609.
22. Zhang H-G et al. Application of a fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression. J Virol 1998; 72: 2483-2490.
23. Ilan Y et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 1997; 94: 2587-2592.
24. Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Characterization of human proliferative T cell response to adenovirus. J Infect Dis 1995; 171: 1090-1096.
25. Smith CA, Woodruff LS, Kitchingman GR, Rooney CM. Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro. J Virol 1996; 70: 6733-6740.
26. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
27. Ma Y et al. Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer. J Immunol 1998; 161: 1516-1524.
28. Fukaura H et al. Induction of circulating myelin basic protein and proteolipid protein-specificc transforming growth factor-β-1 secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996; 98: 70-77.
29. Pohl-Koppe A et al. Identification of a T cell subset capable of both IFN-γ and IL-10 secretion in patients with chronic Borrelia burgdorferi infection. J Immunol 1998; 160: 1804-1810.
30. Molnar-Kimber KL et al. Impact of pre-existing and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trila for localized mesothelioma. Hum Gene Ther 1998; 9: 2121-2133.